Health Care Model For Patients Research Articles

Model development of patient\'s dental and oral health care in raden mattaher hospital, Jambi Province

Dental and oral health care is the primary role and authority of the Dental and Oral Therapist. This study aims to develop a dental and oral health care model for patients in the dental polyclinic of Raden Mattaher Hospital. This quantitative study used an applied research design to develop a model of dental and oral health care. Eleven dental nurses were involved as informants, and three dentists as key informants. This research was conducted at the dental polyclinic of the Jambi Provincial Hospital from March to November 2022. The data were obtained through interviews, focus group discussions (FGD), observations, and trials of the draft model of the patient's dental health examination. Furthermore, a trial of the dental health care model was carried out on people with a mental health conditions. The total score on the questionnaire results of the HELISIDI dental and oral health care model was 546, with a presentation of 76% based on the eligibility criteria. These results mean that the HELISIDI Model is eligible but with revisions. The total score for the HELISIDI dental and oral health care status card was 546, with a presentation of 87% based on the eligibility criteria. According to the respondent, the HELISIDI Status Card is eligible but with revisions. After revision, the model and the HELISIDI status card were declared eligible without further revision. The model of dental and oral health care for patients at the dental clinic of Raden Mattaher Hospital is suitable for mental patients.

Challenges of managing diabetes in Iran: meta-synthesis of qualitative studies

BackgroundAlthough several diabetes management and control programmes are introduced in Iran, many patients do not achieve diabetes-related clinical goals as recommended. The aim of this study was to identify the qualitative evidence for the challenges regarding diabetes management.MethodsA systematic review of qualitative studies following PRISMA guidelines was undertaken. Scopus, PubMed, Science Direct, and Web of Knowledge were searched as well as Persian databases including Magiran, Irandoc and SID from inception to August 2019. The included Studies were either in English- or Persian-language qualitative studies reporting the perspectives of patients, their relatives, or healthcare service providers. Content of the findings were analysed and organized according to Chronic Care Model framework.ResultsTwelve studies met the inclusion criteria. Six main themes were identified including holistic understanding of patients, leadership and governance difficulties, service delivery, workforce, financing, and information and research.ConclusionChallenges regarding the management of diabetes in Iran is multifaceted. Reforming the health care system or developing complementary strategies is essential to improve suitable health care model for patients with chronic conditions such as diabetic patients.

An (Almost) Perfectly Competitive Health Care Model for Patients that Minimizes Cost, Maximizes Satisfaction, Manages Medical Payments, and Generates Health Care Competition

The American health care system does not operate in an actual free market environment. The patient cannot manage his or her healthcare services and control his or her costs. This paper will discuss three of the requirements for perfect competition: (1) Many buyers, (2) Many sellers and (3) Perfect information. The meeting place for the solution to these requirements will generate an almost perfectly competitive market for medicine and return almost complete control to the patient. This meeting place will be an online auction/marketplace service. The service will act as a reverse auction or marketplace with competing providers bidding down prices to fill available slots in their services. The system will use current medical coding numbers to allow comparative pricing. Services can be bundled or sought individually by both the patient and the provider. Patients can choose how long to wait, how far to travel, and how much they want to pay before deciding on the provider.

The Care Continuum: An Evolving Model for Care and Research in Rare Diseases.

* Abbreviation: FDA — : US Food and Drug Administration Based on advances in our understanding of genetics and pathophysiology, we are in the midst of an exciting therapeutic development period in rare diseases. The Orphan Drug Act defines as rare conditions those affecting <200 000 individuals in the United States.1 Examples of rare diseases include cystic fibrosis, hemophilia, spinal muscular atrophy, and most lysosomal storage diseases. Collectively, rare diseases are common, affecting almost 30 million individuals in the United States.2 Unfortunately, patients with rare diseases experience barriers to comprehensive care, and 95% of rare diseases lack US Food And Drug Administration (FDA)-approved disease-specific treatments. Key barriers to the delivery of high-quality care and therapeutic innovation include lack of access to disease experts, limited knowledge of disease course, and few partnerships between disease stakeholders. We propose a new health care model for patients with rare diseases, called the Care Continuum Model, which focuses on 3 concepts: (1) telehealth; (2) integration of care and research; and (3) improving patient–clinician–researcher collaboration. Traditional health care involves local delivery of care. This model does not meet the needs of patients with rare diseases. These disorders often require multidisciplinary expert care, and individually affect small numbers of individuals dispersed over wide geographic areas. Consequently, diagnosis is delayed, and distance and disability limit access to ongoing care. The Orphan Drug Act stimulated therapeutic development for rare diseases … Address correspondence to Erika F. Augustine, MD, MS, Center for Human Experimental Therapeutics, University of Rochester Medical Center, 601 Elmwood Ave, Box #631, Rochester, NY 14642. E-mail: erika_augustine{at}urmc.rochester.edu

The U.S. Thrombosis and Hemostasis Centers pilot sites program

Venous thromboembolism (VTE) is a common disorder associated with significant morbidity and mortality. Despite important advances in understanding the etiology of VTE, delivery of care to patients with thrombosis and thrombophilia is frequently incomplete and highly variable. A comprehensive model of health care has been used successfully to treat and prevent complications for people with hemophilia and other chronic disorders. The effectiveness of an integrated healthcare model for patients with all coagulation disorders has yet to be evaluated. The Division of Hereditary Blood Disorders of the Centers for Disease Control and Prevention (CDC) is collaborating with eight Thrombosis and Hemostasis Centers (pilot sites) to provide health-related services and conduct research directed toward the reduction or prevention of complications of thrombosis and thrombophilia. The initial objectives of the collaboration are to (1) determine the efficacy of integrated multidisciplinary care and prevention services for people with hemostatic disorders, (2) assess unmet needs for service delivery and identify outreach strategies to improve access to care, (3) develop effective messages aimed at disease management and prevention, and (4) foster the development of training programs to enhance provider skills for the delivery of patient care. To address these objectives, the investigators and CDC have developed and implemented a web-based patient registry to follow prospectively service allocation and patient outcomes. Funding for the program began in October 2001. All eight funded centers are affiliated with U.S. medical schools. Principal investigators at the centers are hematologists (five adult, two pediatric) or cardiologists. Faculty in obstetrics-gynecology, surgery, and multiple other specialties are integral to the model of care at the centers. Other critical components at the centers are clinical laboratory services, training programs, research networks, and education and outreach programs. From August 2003 to March 2006, over 2,600 patients were enrolled in the registry, accounting for a total of more than 5,000 visits to the centers. Immediate goals of the data collection at the centers are to characterize patients receiving care at centers and document the state of health services provided. Long-term goals are to evaluate prospectively clinical outcomes for patients receiving multidisciplinary care and prevention services at centers. The network of data collection across centers will facilitate future collaborative clinical and epidemiologic investigations and enhance collective expertise in hemostasis and coagulation disorders.